Drug Trial Radar · NCT01817322
Kidney Graft Function Under the Immunosuppression Strategies
Last checked: Nov 19, 2026Latest source record: Oct 3, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Jun 2011
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- Samsung Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To demonstrate that cyclosporine-sparing immunosuppressions with the standard dose of Enteric-Coated Mycophenolate Sodium would preserve renal graft function after transplantation without an increase of incidences of adverse events, such as biopsy confirmed acute rejection, local or systemic infections, and bone marrow suppression.
Conditions
- Chronic Renal Disease
Interventions
Standard Dose of Myfortic and Reduced Dose of MyforticDrug
Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)
Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental groupDrug
500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
Basiliximab injected both control group and experimental groupDrug
The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
Primary outcomes
What the sponsor says the trial is designed to measure.
- eGFR (abbreviated MDRD equation)Time frame: 6 months after transplantation
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.